The selection of an anesthetic agent is a critical decision in perioperative medicine, with optimal patient recovery being a key goal. Propofol, one of the most widely used intravenous sedatives worldwide, has been extensively studied in comparison with inhaled anesthetics, traditional sedatives, and newer agents. Across a range of clinical contexts, researchers have studied propofol in relation to other anesthetic agents and have found advantages in many clinical situations, particularly regarding patient recovery following procedural sedation.
In the context of general anesthesia for ambulatory surgery, a systematic review and meta-analysis by Gupta et al. examined recovery profiles following maintenance anesthesia with propofol, isoflurane, sevoflurane, and desflurane across 58 randomized controlled trials.1 The authors found that early recovery, measured by time to eye opening and time to obeying commands, was statistically faster with desflurane and sevoflurane compared with both propofol and isoflurane, though the magnitude of these differences was clinically modest—generally fewer than five minutes. Notably, propofol demonstrated a significant advantage in postoperative nausea and vomiting (PONV): when all inhaled anesthetics were pooled, the incidence of postoperative nausea was 25.8% in the inhaled group versus 14.1% in the propofol group, and post discharge vomiting was 15.6% versus 5.9%, respectively.1 These findings suggest that while inhaled agents may confer marginal speed advantages in early awakening, propofol’s favorable side-effect profile—particularly the reduced burden of PONV—may render it a more suitable choice for many ambulatory patients.
In the domain of procedural sedation, propofol has demonstrated distinct advantages over traditional sedative regimens. A meta-analysis by Wang et al. encompassing 1,798 patients and 22 randomized controlled trials focused on endoscopy procedures found that propofol sedation was associated with significantly shorter recovery times (weighted mean difference [WMD] −19.75 minutes; 95% CI −27.65 to −11.86) and discharge times (WMD −29.48 minutes; 95% CI −44.13 to −14.83) compared with benzodiazepine-based agents. Propofol also produced higher post-anesthesia recovery scores, better sedation quality, and improved patient cooperation. Crucially, the incidence of cardiopulmonary complications—including hypoxia, hypotension, arrhythmia, and apnea—did not differ significantly between propofol and traditional sedatives, even in high-risk subgroups such as octogenarians and patients with cirrhosis.2 The principal drawback identified was a significantly higher incidence of pain on injection with propofol. These data establish propofol as a safe and efficient agent for endoscopic sedation with meaningful benefits for patient recovery relative to other anesthetic agents capable of providing sedation.
The neurophysiological basis of propofol-induced unconsciousness has been elucidated at a mechanistic level by Lewis et al., who recorded multiscale neural activity—including single-unit firing, local field potentials, and intracranial electrocorticograms—during propofol induction in human subjects.3 Their findings revealed that loss of consciousness coincides with the abrupt onset of slow oscillations (<1 Hz) in the local field potential, occurring within seconds of drug administration. These slow oscillations fragment cortical activity both temporally and spatially: neuronal spiking becomes restricted to brief “ON” periods coupled to the oscillation phase, while distant cortical regions become functionally desynchronized. Although local network connectivity was largely preserved, long-range communication between cortical areas was markedly impaired.3 This mechanistic account helps explain the rapid and reliable induction of unconsciousness characteristic of propofol, as well as its equally rapid offset once the drug is discontinued.
A more recent randomized controlled trial by Kim et al. compared recovery from intraoperative sedation with propofol, dexmedetomidine, and remimazolam—a novel, ultrashort-acting benzodiazepine—in patients undergoing upper limb surgery under brachial plexus blockade.4 Propofol yielded the shortest mean recovery time at 12 minutes (95% CI 10–13), compared with 17 minutes for remimazolam (95% CI 15–19) and 19 minutes for dexmedetomidine (95% CI 16–22), with all pairwise comparisons reaching statistical significance.4 Secondary outcomes, including post anesthesia care unit length of stay and quality of recovery scores, did not differ significantly among groups. However, propofol was associated with a higher incidence of respiratory depression and oxygen desaturation relative to remimazolam and dexmedetomidine, and it produced significantly more injection pain. Surgeon satisfaction was also lower in the propofol group, attributed to higher rates of intraoperative patient movement.4
Taken together, the available evidence positions propofol as an agent with reliably rapid recovery kinetics, favorable antiemetic properties compared to some other common anesthetic agents, and well-characterized neurophysiological mechanisms of action. Nevertheless, its potential to cause respiratory depression and injection-related discomfort must be considered. Newer alternatives such as remimazolam offer competitive recovery profiles with potentially improved safety margins, though propofol’s established track record and overall favorable dynamics remain clinically relevant. Continued comparative research across diverse procedural contexts will be essential to optimizing sedation and anesthetic strategies for individual patient needs.
References
1. Gupta, A. et al. Comparison of recovery profile after ambulatory anesthesia with propofol, isoflurane, sevoflurane and desflurane: a systematic review. Anesth. Analg. 98, 632–641 (2004).
2. Wang, D. et al. The use of propofol as a sedative agent in gastrointestinal endoscopy: a meta-analysis. PLoS ONE 8, e53311 (2013).
3. Lewis, L. D. et al. Rapid fragmentation of neuronal networks at the onset of propofol-induced unconsciousness. Proc. Natl Acad. Sci. USA 109, E3377–E3386 (2012).
4. Kim, H.-J. et al. Comparison of the recovery profiles of propofol, dexmedetomidine, and remimazolam for intraoperative sedation in patients undergoing upper limb surgery under brachial plexus blockade: a randomized controlled trial. Can. J. Anesth. 72, 1090–1100 (2025).